Shield Therapeutics discuss their Chinese licencing agreement plus John Meyer on Sirius and Arc Minerals
Justin Waite
Vox Markets Podcast with Justin Waite
13:02, 8th January 2020

Vox Media Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app


On today's Vox Markets Podcast: Shield Therapeutics discuss their Chinese licencing agreement plus John Meyer on Sirius and Arc Minerals

Carl Sterritt, CEO of Shield Therapeutics (STX) FOLLOW discusses their exclusive licence agreement in China for the development and commercialisation of Feraccru®/Accrufer®.

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. The Group's lead product, Feraccru®/ Accrufer® has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland. In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV and in the USA the product will be marketed as Accrufer® with Shield currently in the process of selecting a commercialisation partner.


John Meyer, Mining analyst and partner at SP Angel talks about gold plus:

Anglo American (AAL) FOLLOW

Sirius Minerals (SXX) FOLLOW

Arc Minerals (ARCM) FOLLOW

(Interview starts at 7 minutes 32 seconds)  

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist